The results validate CtBP2 as a key modulator of metabolic–epigenetic crosstalk, suggesting that its inhibition can disrupt cancer cell proliferation through redox balance and metabolic regulation; thus, CtBP2 could be a potential therapeutic target in TNBC. Here, CTBP2 is linked to cancer.